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Summary Cloned cell lines of chemically-induced murine fibrosarcomas maintained in tissue culture usually
fail to grow when transplanted to normal syngeneic mice. They grow, however, in various categories of T cell
deficient mice and after such passage grow readily in normal mice. Both cultured and mouse-passaged lines
possess strong TATA.
Three alternative explanations are suggested which might account for these findings.
1. Emergence during the initial passage of a population of tumour cells resistant to NC cells.
2. Acquisition during the initial passage of a protective surface molecule that interferes with the efferent side
of the immune response when the tumour cells are subsequently transplanted to a normal host.
3. Loss during the initial passage of a Class I MHC molecule which prevents dual recognition of the tumour
cells by T cells when they are transplanted to a normal host.
New experiments are proposed to distinguish between these possibilities.
As we have already reported (Woodruff, 1982a;
1984b), many in vitro - propagated cloned cell lines,
and some uncloned lines, from strongly
immunogenic methylcholanthrene-induced murine
fibrosarcomas fail to grow when transplanted s.c.
(1-2 x 106 viable cells) to normal syngeneic hosts,
whereas cells from the primary tumours that have
not been propagated in vitro are readily
transplantable. A similar decline in tumorigenicity
in vivo as a consequence of propagation in vitro has
been reported in respect of murine respiratory
carcinomas by Jamasbi & Nettesheim (1977, 1979).
In our experiments, cell lines that failed to grow
in normal adult syngeneic mice grew readily in
thymectomized, heavily irradiated (7.3 Gy)
syngeneic mice protected with cytosine arabinoside,
sublethally irradiated (4.7Gy) syngeneic mice, and
syngeneic or allogeneic adult nude mice, and after
such passage usually grew in normal mice. To
account for these findings we postulated firstly that
in vitro passaged lines are susceptible in vivo to
combined attack by T cells and NK (or similar)
cells but may escape if either component is missing;
and secondly that, during passage in hosts deficient
in T but not NK cells, a tumour cell population
emerges that is NK cell resistant and can therefore
grow in normal mice. The expression "NK (or
similar) cells" is used here in a broad sense to
include all cells which exhibit cell-mediated
cytotoxicity which is non-acquired, i.e. is not
contingent on previous specific priming or non-
specific activation of some kind.
In the mouse there are at least two kinds of cell
which conform to this definition, distinguished inter
alia by the kinetics of target cell lysis, expression of
cell-surface antigens, and age at which their activity
first becomes manifest. There is much to be -said for
referring to these simply as NK (type 1) and NK
(type 2) cells, but in the absence of any general
agreement to this effect we have reluctantly
adopted Stutman's terminology (Stutman et al.,
1978), using NK as the label for cells which kill in
short term (4h) in vitro assays, and NC for those
whose activity is demonstrated only in more
prolonged (15-24h) assays, despite the objection
that both categories of cell are cytotoxic and
cytocidal.
To investigate the matter further we have
embarked on a comparative study of the
tumorigenicity, immunogenicity, sensitivity to cell-
mediated cytotoxicity (CMC) and surface markers
of cultured lines, and lines passaged in normal and
deprived hosts, including newborn normal and
athymic (CBA nu/nu) mice. These last two
categories were added to those tested previously
because both have been reported to show little or
no evidence of NK (as distinct from NC) activity
before the age of 3 weeks (Herberman et al., 1975;
Kiessling et al., 1975; Kiessling & Wigzell, 1979),
andthereisevidence(Lattimeetal., 1983)thatsarcoma
targets may be killed in vitro by NC or NK cells
alone, or in combination.
Observations on NK and NC activity in our
mice, and on the sensitivity of our tumour lines to
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these cells in vitro, will be reported in a subsequent
paper. Here we present the results of in vivo studies
on the tumorigenicity and immunogenicity of
cultured and mouse-passaged lines, and discuss
possible reasons for the differences observed.
Materials and methods
Tumours and clones
Forty-six cloned cell lines were studied in all,
derived from three different fibrosarcomas,
designated W319 (previously referred to as Dl1),
W321 (D13) and W324 (S10), which had been
induced with methylcholanthrene in female CBA
backcross mice heterozygous for the A and B
alloenzymes of phosphoglycerate kinase-1 (PGK-1).
The origin and properties of these tumours, and the
techniques of tissue culture, transplantation, cloning
and alloenzyme analysis, have been described
previously (Woodruff et al., 1982a).
Cultured cloned lines (C lines) were maintained
by repeated subculture and samples were stored
from time to time in liquid nitrogen. Mouse-
passaged lines (M lines) were established by passage
in an irradiated mouse followed by repeated
passage in normal mice. Cells from M lines were
sometimes grown for 24 or 48h in culture before
being used experimentally; these are referred to as
MC cells.
There were 20 PGK-l A clones (W319 clones 6,
7, 10, 13, 15, 16, 18, 24, 25, 27, 30, 35, 36, 37, 40;
W321 clone 7; W324 clones 10, 17, 23, 27), 22
PGK-I B clones (W319 clones 1-5, 8, 9, 11, 12,
14, 17, 23, 26, 28, 29, 32, 33, 34; W324 clones 30,
32, 49, 57) and 4 clones (possibly hybrid cells)
expressing both A and B alloenzymes (W324 clones
2 (reclone 11), 8, 9 and 16). The number of
different clones (excluding the possible hybrids) was
clearly not less than 5 (an A clone and a B clone
from W319, a clone from W321, and an A clone
and a B clone from W324); statistical considerations
and cross-immunization experiments reported else-
where (Woodruff & Hodson, in preparation)
suggest that it was probably not greatly in excess
of this number despite appreciable phenotypic
diversity among clones of the same alloenzyme
type. Two clones (W319 clones 6 and 12) of
different alloenzyme type, which have been shown
(Woodruff et al., 1984a) to be immunologically
non-cross reactive in respect of their tumour-
associated transplantation antigens (TATA), have
been chosen for more detailed investigation.
Mice
Female CBA/Ca mice were purchased from Bantin
and Kingman Ltd., Hull, England. Adult and
weanling CBA backcross nude mice (CBA nu/nu),
and pregnant females to provide newborn CBA
nu/nu and nu/+ mice, were obtained from the
Medical Research Council Clinical Research
Centre, Harrow, England. Backcross Balb/c nu/nu
mice were purchased from G.L. Bolmhotgard Ltd.,
8680 RY, Denmark,
Irradiation
Mice were irradiated as described previously
(Woodruff et al., 1984a) with a Siemens Stabiliplan
X-ray machine operating at 250kv; the dose rate
was 0.37Gymin'- and the total dose was
4.7Gy+5%.
Cell suspensions were irradiated in siliconized
glass bijoux bottles or Eppendorf polypropylene
centrifuge tubes, with a 60Co source at
2.8Gymin 1 (total dose 220Gy).
Assessment oftumorigenicity
Adult and weanling mice were given a sub-
cutaneous (s.c.) injection of viable tumour cells
(usually 1-2 x 106) to a hind limb. The thickness of
the limb was measured twice weekly with a caliper
and the end point was defined as the time when the
difference in thickness between the injected and
control limbs reached 5mm. Mice which did not
develop tumours were sacrificed after 3 months.
Newborn mice received a s.c. injection of 2 x 105
viable tumour cells to the back. Measurements were
made of the base of the tumour in two directions at
right angles, and of the maximum height of the
tumour above the skin. As a rule the end point was
taken as the time when the product of these
measurements was - 500mm3.
Assessment ofimmunogenicity
Mice were injected s.c. in one hind limb with 106
irradiated or viable untreated tumour cells, or with
material obtained by freezing and thawing tumour
cells 3 times in a syringe; 14 days later they were
challenged by injecting viable cells to the opposite
limb. If tumours developed they were measured as
described above. The numbers of cells used for
challenge depended on the clone used and the
number of generations for which it had been
passaged in vitro. The dose chosen was such that
tumours in control mice reached their end point in
2-3 weeks. The immunogenicity index (I) was
calculated as previously described (Woodruff et al.,
1982b) according to the formula
mean increase in limb
thickness in immunized mice
I=100 I
mean increase in limb
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on the day when the denominator of the fraction
first exceeded 5 mm.
In some experiments the mice were challenged
with cells that had been labelled with [1251I]UDR as
described below, and the disappearance of label was
monitored by external counting with a scintillation
detector (Probe type 235, D.A. Pitman Ltd., fitted
with a lead shield with a 16 mm diam. window)
connected to a scaler (MS 310, J. and P. Engineering,
Reading, England). Before the injection a mark was
made on the outer side of the shaved hind limb and
a second mark exactly opposite on the inner side of
the limb. The cells were injected in a volume of
0.05ml, the tip of the needle being located exactly
under the first mark. The second mark was used as
a guide when counting to ensure that the injection
site was centred in the window of the detector. The
mouse counts, after subtraction of background
(<0.2% of the initial counts), were standardized by
reference to an external standard counted at the
same time.
Labelling of tumour cells with [1251 UDR
Cells in long-term culture, or in cultures set up the
previous day from a mouse, in 75cm2 tissue culture
flasks were labelled by replacing the medium
(MOPS buffered Ham's FIO medium with 10%
FCS) with 20ml medium containing 8 jiCi
[1251]UDR (Amersham International, Amersham,
England) and 3 ,g fluorodeoxyuridine (FUDR),
and incubating for 18 h at 37°C. The cells were then
harvested in the usual way with trypsin-EDTA,
washed twice in medium without FCS, and
resuspended in medium without FCS (2 x 107 viable
cellsml-).
Results
Tumorigenicity ofcultured and mouse-passaged
cloned tumour lines
After s.c. injection of a standard dose of viable cells
(1-2 x 106 for adult and weanling, and 5 x 105 for
newborn, mice) only 6 of the 46 lines tested grew in
normal adult CBA mice, whereas all the lines tested
(ranging in numbers from 40 to 5) grew in
irradiated CBA mice; adult, weanling and newborn
CBA nu/nu; newborn CBA nu/+; and adult Balb/c
nu/nu (Table I). A small scale trial was undertaken
of doses ranging from 6 x 103 to 5 x 106 viable cells
Table I Growth of unpassaged cloned lines in normal and immunodeficient mice after subcutaneous injection of
a standard dose of viable cells.
No. of Days to
mice which No. of No. and identity end-pointb
Cell dose No. of developed clones ofclones which
Type of host (millions) mice tumours tested grew Range, Median
Untreated adult 1-2 166 10 46a 6 15-
CBA (W319 C5, 8, 10, 13,
24,35)
Irradiated (4.95Gy) 1-2 117 111 40 40 11- 48
adult CBA (W319 C1-18, 23-30,
32-37,40;W324 C2,
8,9,10,17,49,57)
Adult CBA 1 21 21 8 8 27-45 35
nu/nu (W319 C1,6,9, 12, 16;
W324 C2,17,49)
Weanling CBA 1 20 20 8 8 22-42 33
nu/nu (W319 C1,6,9, 12, 16;
W324 C2,17,49)
Newborn CBA 0.5 16 14 6 6 24- 34
nu/nu (W319 C1,6, 12, 16;
W324 C17,49)
Newborn CBA 0.5 21 19 5 5 20- 34
nu/+ (W319 C1,6, 12,16;
W324 C49)
Adult Balb/c 1 15 15 5 5 23-37 31
nu/nu (W319 C1,6, 12, 16;
W324 C49)
aListed in text. The 40 clones that failed to grow were tested in at least 2 mice at a dose of 2 x 106 viable cells.
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(Table II). Two cultured lines (W319, C6 and C12),
which had failed to grow after inoculation of
2 x 106 cells also failed at a dosage of 5 x 106 cells.
Cultured line W319 C5, which grew in normal mice
after inoculation of 2 x 106 cells failed at lower
doses, whereas 4 of 4 cultured lines tested
(including W319 C5) grew in irradiated mice after
inoculation of 6 x 103 or 2 x 104 cells.
After a single passage in irradiated mice, 33 of 39
clones tested grew in normal mice. All clones tested
(ranging in numbers from 8 to 5) grew in normal
mice after passage in adult, weanling and newborn
CBA nu/nu, and newborn CBA nu/+; and 3 of 5
clones grew in normal mice after passage in
allogeneic adult Balb/c nu/nu (Table III).
One mouse-passaged line (W319 C6M), which
Table II Growth of unpassaged cloned lines in normal and irradiated mice after s.c.
injection ofviable cells in various doses.
Proportion ofmice developing tumours at the cell dose shown
Clone Host 5 x 106 2X 106 X.106 2x105 6x104 2x104 6x 103
319 C4 Untreated CBA 0/2 0/2 0/2 0/2
Irradiated CBA 2/2 1/1 1/1 1/1
319 C5 Untreated CBA 2/2 0/1 0/1 0/1 0/1
Irradiated CBA 2/2 1/1 1/1 1/1 1/1
319 C6 Untreated CBA 0/4 0/10 0/7
Irradiated CBA 2/2 7/7
319 C12 Untreated CBA 0/3 0/8 0/7
Irradiated CBA 4/4 7/7
319 C13 Untreated CBA 1/2 0/1 0/1 0/1 0/1
Irradiated CBA 2/2 1/1 1/1 1/1 1/1
319 C35 Untreated CBA 2/2 0/2 0/2
Irradiated CBA 2/2 1/1 1/1
Table III Growth in normal mice ofcloned lines passaged in immunodeficient mice
Growth in normal host
No. of Days to
mice which No. of No. and identity End-pointc
Cell dose No. of developed clones ofclones which
Immunodeficient host (millions) mice tumours tested grew Range Median
Irradiated adult 1-2 132 88 39a 33 7- 21
CBA (W319 Cl,2,4-13,15
16,18,23-30,32-37
W324 C2,17,49,57)b
Adult CBA 1 90 76 8 8 8- 26
nu/nu (W319 C1,6,9,12,16;
W324 C2,17,49)
Weanling CBA 1 81 69 9 8 8- 19
nu/nu (W319 Cl,6,9,12,16;
W324 C2,17,49)
Newborn CBA 1 54 40 7 7 9- 19
nu/nu (W319 C1,6,12,16;
W324 C2,17,49)
Newborn CBA I 69 45 6 6 9- 32
nu/+
Adult Balb/c 1 45 9 5 3 12-
nu/nu
-W319 C1-18, 23-30, 32-38; W324 C2,8,10,17,49,57
bi.e. All except W319 C3,14,17,40; W324 C8, 10
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had been passaged first in an irradiated mouse and
then in normal mice, was returned to culture and
then re-tested in vivo. The culture flasks (75cm2)
were seeded at different densities (105 to 107 viable
cells/flasks); they were not subcultured but the
medium was changed as required. When the
cultures were almost confluent the cells were
harvested and injected s.c. to normal CBA mice.
The results are shown in Table IV, from which it
will be seen that the ability to grow was unimpaired
after 1-36 days in culture but completely lost after
70 days. Five other mouse-passaged lines (W319
Cl, C12, C16, C17; W324 C57) were cultured in
vitro for 48 h and re-tested in normal mice, All grew
readily from 106 viable cells whereas the
corresponding long-term cultured lines failed to
grow from either 106 or 2 x 106 viable cells.
Immunogenicity ofcultured and mouse-passaged
cloned tumour lines
The growth of tumours after challenge with viable
mouse-passaged cells in mice immunized with
various doses of viable cultured, irradiated cultured
or irradiated mouse-passaged cells is shown in
Table V.
Both the mouse-passaged and the cultured cell
lines clearly possess strong TATA. There is a
suggestion that irradiation in the dose used may
have reduced the immunogenicity of the cultured
cells, but the effect, if any, is small. There is no
evidence of a significant difference in immuno-
genicity between irradiated cells from the mouse-
passaged and corresponding cultured lines, despite
the fact that the number of neoplastic cells in the
immunizing inoculum was at least 20% less in the
case of the mouse-passaged cells owing to the
presence of macrophages and other non-neoplastic
cells which were included in the total count.
Incidence of tumours and disappearance oflabel after
injection of['251]UDR-labelled W319 C6 cells to non-
immunized mice
The results are shown in Figures 1 and 2.
It seems clear that the tumorigenicity of viable
cells in appropriate hosts was not altered by the
labelling procedure.
The loss of label after injection of viable cells to
normal hosts cannot be expressed by a single
exponential function, which would correspond to a
single straight line when the logarithm of counts
per minute (cpm) is plotted against time. It can,
however, be expressed approximately by two or
three exponential functions with different specific
rates.
After injection of the cultured line (Figure 1) two
phases can be distinguished, with a markedly higher
specific rate from Day 6 onwards. We attribute this
higher rate to the development of an immune
reaction to TATA since it did not occur in
irradiated mice.
After injection of mouse-passaged cells (Figure 2)
the specific rate of loss was relatively high for 24h
(not plotted in detail), possibly owing to the
presence in the inoculum of labelled dead or
damaged cells. From Day 1 to Day 5 the rate was
slower than the initial rate, and slower also than
the rate observed with cultured cells at the
corresponding time. Thereafter the rate increased in
normal but not in irradiated mice, and once again
we attribute this increase to the development of
immunity to tumour antigens.
After injection of irradiated (220 Gy) labelled
cultured or mouse-passaged cells to normal mice,
label was lost more quickly than after injection of
viable cells of the same kind, and the specific rate
of loss appeared to increase continuously after 24h,
with no clear-cut distinction between phase 2 and
phase 3.
Table IV The effect of a further period in tissue culture on the tumorigenicity of a
mouse-passaged cloned line (W319 C6 M) in normal mice.
No. ofmice
which
No. ofviable developed
cells used Days in No. ofcells tumour
to set up tissue injected No. ofmice within Days to
culture culture (millions) injected 2 months end-point
0 1 4 4 10,10,10,11
107 1 1 4 4 12,12,15,15
106 20 1 4 4 11,11,11,14
106 20 2 4 4 7,9,9,10
3x105 36 1 4 4 10,12,12,13
105 70 1 4 0166 M.F.A. WOODRUFF & B.A. HODSON
Table V Immunogenicity of cultured and mouse-passaged cloned tumour cell lines.
Cells usedfor immunization Proportion
ofmice which Immunogenicity
Irradiated No. of viable mouse-passaged developed index
Clone Source or not Dose cells usedfor challenge tumours %
W319C
C6 Nil (unimmunized controls) 2 x 104 5/5
Cultured no 106 2 x 104 0/5 100
105 2 x 104 0/5 100
104 2 x 104 2/5 75
yes 106.5 2 x 104 0/5 100
106 2 x 104 0/5 100
105 2 x 104 0/5 100
104 2 x 104 3/5 66
Mouse- yes 106.5 2 x 104 0/5 100
passaged 106 2 x 104 0/5 100
105 2x104 0/5 100
104 2x104 5/5 10
W319
C12 Nil (unimmunized controls) 5 x 105 5/5
Cultured no 106.5 5 x 105 2/5 83
106 5 x 105 0/5 100
105 5 x 105 0/5 100
104 5 x 105 1/5 81
yes 106.5 5 x 105 1/5 92
106 5 x 105 1/5 88
105 5x105 1/5 96
104 5 x 105 4/5 39
Mouse- yes 106.5 5 x 105 4/5 67
passaged 106 5x 105 1/5 96
105 5 x 105 1/5 81
104 5 x 105 5/5 33
Label was lost very quickly after injection of cells
which had been frozen and thawed three times.
This was not unexpected, but we were surprised
that enough mouse-passaged cells survived this
procedure to result in the slow development of
tumours in 5 out of 5 irradiated mice and 3 out of
5 normal mice.
Incidtence of tumours and disappearance oflabel after
injection of [1251]UDR-labelled W319 C6 cells to
immunized mice.
The results are shown in Figures 3 and 4.
Pre-treatment with irradiated cells (whether
cultured or mouse-passaged), or non-irradiated
cultured cells, 14 days before challenge with viable
mouse-passaged cells (Figure 4), prevented the
development of tumours and resulted in accelerated
disappearance of label. It seems clear, therefore,
that cultured and mouse-passaged cells are both
immunogenic, and the results do not point to any
clearcut difference in their level of immunogenicity.
Mice challenged with cultured cells did not develop
tumours, irrespective of whether or not they were
pre-immunized, but pre-immunization did result in
somewhat accelerated loss of label (Figure 3).
When mice with established tumours caused by
injection of viable mouse-passaged cells were
challenged with a further injection of labelled
mouse-passaged cells to the opposite hind limb,
tumours developed rapidly at the site of challenge
and the pattern of disappearance of label was
indistinguishable from that seen in previously
untreated mice. In these experiments, therefore,
there is no evidence of concomitant immunity. Pre-
treatment with frozen-thawed cells did not generate
detectable immunity (not plotted).EFFECT OF PASSAGE ON MURINE SARCOMAS
(ecu E E _;, ._,
X in
E E
0 0
CJ)
0
-j
"I
N
'I
\
\-
'N~
7
'N
5/5 (30 d)
Time t (d)
Figure 1 Disappearance of label (measured by external counting) after injection of [1251]UDR-labelled W319
C6 cultured cell line to non-immunized hosts. (0) Viable cells in untreated hosts; (A) Viable cells in
irradiated hosts; (0) Irradiated cells in untreated hosts; (E1) Freeze-thawed cells in untreated hosts. A
virtually identical curve was obtained in irradiated hosts. The vertical bars denote s.e. The numbers on each
curve denote the proportion of mice which developed tumours followed, where appropriate, by the time in
days (median) to reach the end point.
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Figure 2 Disappearance of label (measured by
external counting) after injection of [125I]UDR-labelled
W319 C6 mouse-passaged cells to non-immunized
hosts. (0) Viable cells in untreated hosts; (A) Viable
cells in irradiated hosts; (0) Irradiated cells in
untreated hosts; (Cl) Freeze-thawed cells in untreated
hosts. In irradiated mice the disappearance curve was
virtually the same but 5/5 mice developed tumours.
Median time to end point 30 days. Vertical bars and
numbers as in Figure 1.
Time t (d)
Figure 3 Disappearance of label (measured by
external counting) after injection of [1251]UDR-labelled
W319 C6 cultured cells to immunized and non-
immunized hosts. (0) Non-immunized controls; (x)
Hosts immunized with irradiated cultured or mouse-
passaged cells, or viable cultured cells (results pooled).
Vertical bars and numbers as in Figure 1.
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Figure 4 Disappearance of label (measured by
external counting) after injection of [125I]-UDR-
labelled mouse-passaged cells to immunized and non-
immunized hosts. (0) Non-immunized controls; (x)
Immunized with irradiated mouse-passaged cells. Mice
immunized with irradiated cultured cells yielded a
virtually identical curve; (0) Immunized with viable
cultured cells; (+) Immunized with viable mouse-
passaged cells. Vertical bars and numbers as in Figure
1. In mice immunized with freeze-thawed cultured or
mouse-passaged cells (not plotted) the pattern of loss
of label was the same as in the control.
Discussion
Our data, together with those of Jamasbi et al.
cited below, point to the need for caution in
interpreting studies with cultured human tumour
lines, where there is obviously no possibility of
comparison with lines passaged in the species of
origin. The observed marked difference in tumori-
genicity between mouse-passaged and cultured lines
of murine tumours is important also because of its
wider biological significance. It cannot be dismissed
as an artifact due to residual FCS on the cultured
cells or the loss of particular cell-surface molecules
caused by exposure to trypsin during the process of
cell harvesting because, as we have shown, mouse-
passaged lines that are returned to culture for 48 h
retain their original high tumorigenicity.
A difference in tumorigenicity between cells taken
directly from a mouse and long-term cultured cells,
similar to that which we have found with our
fibrosarcoma lines, was observed by Jamasbi and
his colleagues in experiments with chemically-
induced murine squamous cell carcinomas (Jamasbi
&Nettesheim, 1977, 1979). The tumours werereported
to beinitially highly tumorigenic andweakly immuno-
genic, but to become less tumorigenic and strongly
immunogenic after prolonged tissue culture, and the
difference in tumorigenicity was attributed to the
difference in immunogencity. In many of these
experiments the mice received an immunizing
injection of viable cells followed by amputation of
the tumour-bearing limb and rechallenge. These are
difficult to interpret because metastases frequently
developed from the initial inoculum and it seems
likely that they influenced the response to
challenge, but other experiments, referred to by
Jamasbi et al. but not described in detail, appear to
lend stronger support to their conclusions. So far as
murine fibrosarcomas are concerned, however, the
striking difference in tumorigenicity between
mouse-passaged and cultured cell lines cannot be
attributed to a difference in immunogenicity. All
the cloned lines we have tested possess strong
TATA, and with the two clones studied in detail we
have found no significant difference in
immunogenicity between the corresponding mouse-
passaged and cultured lines, as judged both by the
development of tumours in response to challenge,
and by the kinetics of disappearance of label from
the site of injection of cells labelled with [1251]UDR
in mice immunized by a previous injection of
irradiated tumour cells.
The growth in vivo of a transplanted strongly
immunogenic tumour implies that it has somehow
escaped from T cell-mediated surveillance, and this
in turn implies either that the inoculum contained T
cell resistant tumour cells or that resistance
developed sufficiently quickly for the tumour to
survive despite the reaction it evoked. Our data
show that the capacity to escape may be lost in the
course of tissue culture but may be regained in vivo
if the tumour is transplanted to a host which, on
account of T cell or other deficiency, is unable to
destroy all the potentially tumorigenic cells
sufficiently quickly to prevent this from happening.
We suggested previously that the capacity of our
tumours to grow in normal mice is lost during
culture because, owing to lack of selective pressure,
a population of cells emerges which is susceptible to
destruction by both NK and/or NC cells and T
cells, and that, during passage in mice deficient in T
but not NK cells, these are replaced by cells which
are NK- or NC-resistant, possibly owing to a
surface change which makes them unrecognisable as
appropriate targets, but remain sensitive to T cells.
On re-transplantation to a normal mouse these
passaged tumour cells then become established
sufficiently quickly for further changes to occur so
that the developing tumour is able to resist the T-
cell mediated reaction it evokes.
In the light of the reported absence of significant
NK activity in newborn mice and our observation
that cultured lines passaged in newborns sub-
sequently grew readily in normal adult mice, this
hypothesis seems unlikely to be correct so far as
1)n I\
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NK cells are concerned, though pending further
evidence it cannot be excluded with certainty. So
far as NC cells are concerned there are at present
no grounds for rejecting the hypothesis, but there
are two other possibilities which merit
consideration.
Firstly, during passage in a susceptible host, the
tumour cells might acquire a protective cell-surface
molecule that interferes, possibly in a non-specific
way, with the efferent, though not the afferent, arm
of the immune response. This is certainly
conceivable because antigen released from cells
could immunize whereas only antigen on the cell
surface provides a target for either cell-mediated or
humoral cytotoxicity.
Secondly, during passage, the tumour cells might
lose a molecule necessary for recognition by T cells.
The mouse-passaged tumours used in this study
clearly do not lack TATA but a class I MHC
molecule would seem to be a candidate since the
phenomenon of MHC restriction (Zinkernagel &
Doherty, 1975) raises the possibility that loss of an
MHC molecule required for dual recognition may
provide an escape mechanism for immunogenic
tumours (Woodruff, 1980).
Experiments are in progress to try to distinguish
between these possibilities and to characterize the
molecule or molecules concerned.
We thank Mrs E. Clark for skilled technical assistance;
Dr H.T. Law, Department of Medical Physics, Western
General Hospital, for access to the 60Co irradiation
source; Dr C.R. Coid and Dr S. Rastan of the MRC
Clinical Research Centre for supplying us with CBA
nu/nu mice; Dr J. Hannan, Department of Medical
Physics for lending us the scintillation detector and scaler,
and Mr C. Ferrington for setting up this equipment. We
thank also Prof. H.J. Evans for the privilege of working
in his Unit, and the Medical Research Council, UK, for a
Project Grant.
References
HERBERMAN, R.B., NUNN, M.F. & LAVRIN, D.H. (1975).
Natural cytotoxic reactivity of mouse lymphoid cells
against syngeneic and allogeneic tumours. I.
Distribution of reactivity and specificity. Int. J.
Cancer, 16, 216.
JAMASBI, R.J. & NETTESHEIM, P. (1977). Increase in
immunogenicity of a pulmonary squamous-cell
carcinoma, propagated in vitro. Int. J. Cancer, 20, 817.
JAMASBI, R.J. & NETTESHEIM, P. (1979). Increase in
immunogenicity with concomitant loss of
tumorigenicity of respiratory tract carcinomas during
in vitro culture. Cancer Res., 39, 2466.
KIESSLING, R., KLEIN, E., PROSS, H. & WIGZELL, H.
(1975). Natural killer cells in the mouse. II. Cytotoxic
cells with specificity for mouse Moloney leukaemia
cells. Characteristics of the killer cell. Eur. J. Immunol.,
5, 117.
KIESSLING, R. & WIGZELL, H. (1979). An analysis of the
murine NK cell as to structure, function and biological
relevance. Immunol. Rev., 44, 165.
LATTIME, E.C., PECORARO, G.A., CUTTITO, M.J. &
STUTMAN, 0. (1983). Murine non-lymphoid tumours
are lysed by a combination of NK and NC cells. Int.
J. Cancer, 32, 523.
STUTMAN, O., PAIGE, C.J. & FEO FIGARELLA, E. (1978).
Natural cytotoxic cells against solid tumours in mice.
1. Strain and age distribution and target cell
susceptibility. J. Immunol., 121, 1819.
WOODRUFF, M.F.A. (1980). The Interaction of Cancer and
Host: Its Therapeutic Significance. New York: Grume
and Stratton, p. 135.
WOODRUFF, M.F.A., ANSELL, J.D., FORBES, G.M.,
GORDON, J.C., BURTON, D.I. & MICKLEM, H.S.
(1982a). Clonal interaction in tumours. Nature, 299,
822.
WOODRUFF, M.F.A., ANSELL, J.D., HODSON, B.A. &
MICKLEM, H.S. (1984a). Specificity of tumour
associated transplantation antigens (TATA) of
different clones from the same tumour. Br. J. Cancer,
49, 5.
WOODRUFF, M.F.A., FORBES, G. & GORDON, J. (1982b).
Immunogenicity, macrophage sensitivity, and
therapeutic response to C. parvum of fibrosarcomas
induced in C. parvum-treated and untreated mice.
Cancer Immunol. Immunoth., 12, 255.
WOODRUFF, M.F.A., HODSON, B.A. & ANSELL, J.A.
(1984b). Transplantability of tumour cell clones before
and after passage in immunodeficient hosts. Br. J.
Cancer, 49, 396.
ZINKERNAGEL, R.M. & DOHERTY, P.C. (1975). H-2
compatibility requirement for T cell mediated lysis of
target cells infected with lymphocytic choriomeningitis
virus. Different cytotoxic T cell specificities are
associated with structures coded for in H-2K or H-2D.
J. Exp. Med., 141,1427.